Congress Materials

Medical Information
Gulf Countries
 

This medical information website is intended only for healthcare professionals in the following Gulf Countries (UAE, Oman, Bahrain, Qatar and Kuwait). This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
SelectI am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or KuwaitYes, I am a Healthcare Professional registered to practice in UAE or Oman or Bahrain or Qatar or Kuwait
I am a patient / caregiverNo, go back to the patient portal
SelectI am a patient / caregiverNo, go back to the patient portal
I am a Healthcare Professional in another country.
The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Poster
Saad F, George DJ,  Cookson MS, Saltzstein DR, Tutrone R,  Akaza H,  Bossi A, Brown B, Selby B, Lu S, Walling J,  Tombal B, Shore ND September 11, 2021 AUA 2021 Prostate Cancer

Relugolix vs Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer

View Presentation View Abstract Plain Language Summary
Poster
Saltzstein DR, Shore ND, Saad F, George DJ, Cookson MS, Tutrone R, Bossi A, Brown B, Selby B, Lu S, Walling J, Tombal B September 16, 2021 ESMO 2021 Prostate Cancer

Efficacy and Safety of Relugolix vs Leuprolide in Men with Advanced Prostate Cancer: Clinical Subgroup Analysis from the Phase 3 HERO Study 

View Presentation View Abstract Plain Language Summary
Poster
Bossi A, Shore ND, Tutrone R, Cookson MS, George DJ, Saltzstein DR,  Brown B, Selby B, Lu S, Walling J, Tombal B September 16, 2021 ESMO 2021 Prostate Cancer

Geographical Assessment of Efficacy and Safety of Relugolix: A Subgroup Analysis from the Randomized, Phase 3 HERO Study vs Leuprolide in Men with Advanced Prostate Cancer (APC)

View Presentation View Abstract Plain Language Summary
Poster
Saad F, de Bono J, Barthelemy P, Dorff T, Mehra N, Scagliotti G, Stirling A, Machiels JP, Renard V, Maruzzo M, Higano CS, Gurney H, Healy CG, Bhattacharyya H, Arondekar B, Niyazov A, Fizazi K September 16, 2021 ESMO 2021 Prostate Cancer

Patient-Reported Pain in Men With Metastatic Castration-Resistant Prostate Cancer Receiving Talazoparib: TALAPRO-1

View Presentation View Abstract Plain Language Summary
Poster
George DJ, Agarwal N, Ramaswamy K, Sandin R, Russell D, Hong A, Emir B, Yang H, Gao W, Hagan K, Freedland SJ September 16, 2021 ESMO 2021 Prostate Cancer

Real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC): a Medicare database analysis

View Presentation View Abstract Plain Language Summary
Poster
Mehra N, de Bono JS, Laird AD, Barthelemy P, Delva R, Dorff T, Maruzzo M, Stirling A, Machiels J-P, Dumez H, Renard V, Hopkins JF, Albacker LA, Chen H-C, Healy CG, Chelliserry J, van Oort IM, Scagliotti GV, Fizazi K September 16, 2021 ESMO 2021 Prostate Cancer

TALAPRO-1: Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer (mCRPC) With DNA Damage Response Alterations (DDRm): Exploration of Non-DDR Mutational Landscape and Potential Associations With Antitumor Activity

View Presentation View Abstract Plain Language Summary
Poster
Agarwal N, Azad AA, Fizazi K, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen H-C, Lanzalone S, Niyazov A, Saad F September 16, 2021 ESMO 2021 Prostate Cancer

TALAPRO-3: A Phase 3, Double-blind, Randomized Study of Enzalutamide (ENZA) Plus Talazoparib (TALA) vs Placebo Plus ENZA in Patients (Pts) with DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)

View Presentation View Abstract Plain Language Summary
Poster
Freedland SJ, Sandin R, Tagawa ST, Klaassen Z, Bitting RL, Ramaswamy K, Emir B, Bland C, Hong A, Yang H, Gao W, Song W, George DJ September 16, 2021 ESMO 2021 Prostate Cancer

Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019

View Presentation View Abstract Plain Language Summary
Oral Presentation
Armstrong AJ, Iguchi T, Azad AA, Szmulewitz RZ, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Shore ND, Petrylak DP, Rosbrook B, Zohren F, Yamada S, Haas GP, Stenzl A September 18, 2021 ESMO 2021 Prostate Cancer

Final overall survival analysis from ARCHES: A phase III, randomized, double-blind, placebo-controlled study of enzalutamide + androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer

View Presentation View Abstract Plain Language Summary
Poster
George DJ, Saad F, Pieczonka C, Cookson MS, Saltzstein DR, Tutrone R, Brown B, Lu S, Fallick M, Hanson S, Shore ND February 18, 2022 ASCO GU 2022 Prostate Cancer

Efficacy and Safety of Relugolix in Black Men with Advanced Prostate Cancer: A Subgroup Analysis from the Randomized, Phase 3 HERO Study versus Leuprolide 

View Presentation View Abstract Plain Language Summary